

Provided by:



Acute Leukemia and Myeloid Neoplasms Case Conference 2021-2022

Acute Leukemia and Myeloid Neoplasms Case Conference 2021-2022 - 6/1/2022

June 1, 2022

12:00 PM - 1:00 PM

Perelman Center for Advanced Medicine, Conference room 12-122

Target Audience

This program has been designed for Internal Medicine - Hematology, Internal Medicine - Medical Oncology, Pathology-Anatomic/Pathology-Clinical

Series Educational Objectives

After participating in this regularly scheduled series, participants should be able to:

- 1 Discuss the importance of adequate marrow cellularity. Tracking technique of marrow. Involvement of pathology in educational series.
- 2 Review the standard of care treatment, medications, concomitant medications, risks, benefits and potential toxicity is or how to find out/whom to ask.
- 3 Identify appropriate prophylactic therapies required for patients receiving therapy for acute leukemia.

Accreditation

In support of improving patient care, Penn Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Designation of Credit

Physicians: Penn Medicine designates this live activity for a maximum of 1.00 *AMA PRA Category 1 Credit(s)*[™]. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses: This activity is for **1.00** contact hours.

Pharmacists: This activity is approved for **1.00** contact hours
UAN Number: JA0000324-0000-21-006-L04-P

PAs: Penn Medicine has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria.

This activity is designated for **1.00** AAPA Category 1 CME credit(s). PAs should only claim credit commensurate with the extent of their participation.

Approved for (PSRM) patient safety/risk management designation

Acknowledgement of Commercial Support*

For more information, please contact
Cherylann Lane, Julie Mcdaniel
(215) 662-3181, (267) 970-8367

cherylann.lane@uphs.upenn.edu, mcdjulie@upenn.edu

Check your transcript online at <https://upenn.cloud-cme.com>

None

Disclosure of Relevant Financial Relationships and Unapproved Uses of Products

It is policy at Penn Medicine Office of Continuing Medical and Interprofessional Education for individuals who are in a position to control the content of an educational activity to disclose to the learners all relevant financial relationships that they have with any commercial interest that provide products or services that may be relevant to the content of this continuing education activity. For this purpose, we consider relationships of the person involved to include financial relationships of a spouse or partner.

The intent of this policy is to ensure that Penn CME/CE certified activities promote quality and safety, are effective in improving medical practice, are based on valid content, and are independent of control from commercial interests and free of commercial bias. Peer review of all content was conducted for all faculty presentations whose disclosure information was found to contain relationships that created a conflict of interest relevant to the topic of their presentation. In addition, all faculty were instructed to provide balanced, scientifically rigorous and evidence-based presentations.

The staff in the Office of Continuing Medical and Interprofessional Education (CME and IPCE), have disclosed that they have no relevant financial relationships with any commercial interests related to the content of this educational activity. Any peer reviewer with a potential conflict of interest will recuse themselves from the peer review process.

Name of individual	Individual's role in activity	Name of Ineligible Company(s) / Nature of Relationship(s)
Adam Bagg, MD	Co-Director, Faculty	Nothing to disclose - 02/10/2022
Keith Pratz, MD	Course Director	Advisor-AbbVie, Inc. Advisor-Bristol-Myers Squibb (Relationship has ended) Advisor-Novartis / Amgen (Relationship has ended) Advisor-Jazz Pharmaceuticals (Relationship has ended) Advisor-Astellas (Relationship has ended) Advisor-Astra Zeneca Pharmaceuticals (Relationship has ended) - 01/11/2022
Colleen R Kucharczuk, CRNP	Nurse Planner	Nothing to disclose - 01/21/2022
Robin E Blauser, BSN	Other Planning Committee Member	Nothing to disclose - 11/09/2021
Martin Carroll, MD	Other Planning Committee Member	Consulting Fee-Janssen Pharmaceuticals (J&J) (Relationship has ended) Paid consultant-Cartography - 02/16/2022
Heather DiFilippo, CRNP	Other Planning Committee Member	Nothing to disclose - 11/09/2021
Noelle V. Frey, MD, MSCE	Other Planning Committee Member	Consulting Fee-Kite Pharma (Relationship has ended) Consulting Fee-Syndax Pharmaceuticals (Relationship has ended) Consulting Fee-Sana Biotechnology (Relationship has ended) Grant or research support-Novartis (Advanced Health Media)

		(Relationship has ended) - 01/26/2022
Saar Gill, MD	Other Planning Committee Member	Consulting Fee-Hemogenyx Grant or research support-Interius Grant or research support-Carisma - 02/03/2022
Elizabeth Hexner, MD	Other Planning Committee Member	Grant or research support-Tmunity Therapeutics Membership on Advisory Committees or Review Panels, Board Membership, etc.-Blueprint Medicines Membership on Advisory Committees or Review Panels, Board Membership, etc.-Pharmessentia (Relationship has ended) Membership on Advisory Committees or Review Panels, Board Membership, etc.-American Board of Internal Medicine - 03/24/2022
Kim A Hummel, RN	Other Planning Committee Member	Nothing to disclose - 02/16/2022
Selina Luger, MD	Other Planning Committee Member	Honoraria-Bristol-Myers Squibb (Relationship has ended) Honoraria-AbbVie, Inc. (Relationship has ended) Consulting Fee-Syros and Pluristem (Relationship has ended) - 03/01/2022
Mary Ellen Martin, MD	Other Planning Committee Member	Nothing to disclose - 02/18/2022
Shannon R. Mccurdy, MD	Other Planning Committee Member	Advisor-Bristol-Myers Squibb (Relationship has ended) - 05/12/2022
Jennifer J.D. Morrissette, PhD	Other Planning Committee Member	Honoraria-Novartis (Advanced Health Media) (Relationship has ended) Honoraria-Bayer (Relationship has ended) Stocks or stock options, excluding diversified mutual funds-ThermoFisher - 02/16/2022
Alexander E Perl, MD	Other Planning Committee Member	Consulting Fee-AbbVie, Inc. Advisor-Actinium Consulting Fee-Astellas Advisor-Bristol-Myers Squibb (Relationship has ended) Advisor-Genentech Consulting Fee-Daiichi Sankyo Advisor-Loxo (Relationship has ended) Advisor-Syndax (Relationship has ended) Consulting Fee-Sumitomo Dainippon (Relationship has ended) Consulting Fee-Forma Consulting Fee-Leukemia and Lymphoma Society/BeatAML LLC Grant or research support-AbbVie, Inc. Grant or research support-Astellas Grant or research support-Daiichi Sankyo Grant or research support-Syndax Grant or research support-FujiFilm (Relationship has ended) - 02/04/2022
David L Porter, MD	Other Planning Committee Member	Stocks or stock options, excluding diversified mutual funds-Genentech Honoraria-Novartis

		(Advanced Health Media) (Relationship has ended) Honoraria-Bristol-Myers Squibb (Relationship has ended) Honoraria-Gilead Sciences, Inc (Relationship has ended) Honoraria-Janssen Pharmaceuticals (J&J) Honoraria-Jazz (Relationship has ended) Membership on Advisory Committees or Review Panels, Board Membership, etc.-DeCART (Relationship has ended) Membership on Advisory Committees or Review Panels, Board Membership, etc.-Bluebird Bio (Relationship has ended) Honoraria-Kadmon (Relationship has ended) Grant or research support-Novartis (Advanced Health Media) Royalties or Patent Beneficiary-Novartis (Advanced Health Media) Royalties or Patent Beneficiary-Tmunity Honoraria-Wiley publishing Honoraria-Am Society for Transplant and Cell Therapy - 02/22/2022
Jacqueline Smith, CRNP	Other Planning Committee Member	Nothing to disclose - 11/16/2021
Kalpana Suresh, MD	Other Planning Committee Member	Nothing to disclose - 11/02/2021
Alison W Wakoff Loren, MD, MSCE	Other Planning Committee Member	Nothing to disclose - 01/12/2022
Craig Freyer, PharmD	Pharmacy Planner	Consulting Fee-Servier (Relationship has ended) Consulting Fee-EUSA (Relationship has ended) Speakers Bureau-Astellas - 05/08/2022
Linda Perry, PA-C	Physician Assistant Planner	Paid consultant-Kadmon Speakers Bureau-AbbVie, Inc. Paid consultant-Incyte Corporation Speakers Bureau-Incyte Corporation - 11/09/2021

Relevant financial relationships are those relationships in which the individual benefits by receiving a salary, royalty, intellectual property rights, consulting fee, honoraria, ownership interest (e.g., stocks, stock options or other ownership interest, excluding diversified mutual funds), or other financial benefit. Financial benefits are usually associated with roles such as employment, management position, independent contractor (including contracted research), consulting, speaking and teaching, membership on advisory committees or review panels, board membership, and other activities from which remuneration is received or expected